Voya Investment Management LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 236.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 177,549 shares of the medical research company's stock after buying an additional 124,739 shares during the quarter. Voya Investment Management LLC owned approximately 0.11% of IQVIA worth $47,734,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in IQV. Pension & Wealth Management Advisors Inc. purchased a new stake in IQVIA in the 3rd quarter worth $30,000. Compass Financial Management LLC purchased a new position in IQVIA during the second quarter valued at $27,000. Elevation Wealth Partners LLC lifted its holdings in IQVIA by 218.8% during the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company's stock valued at $30,000 after purchasing an additional 105 shares in the last quarter. Balance Wealth Partners LLC acquired a new stake in shares of IQVIA in the third quarter valued at about $43,000. Finally, Caitlin John LLC acquired a new stake in shares of IQVIA in the second quarter valued at about $31,000. Hedge funds and other institutional investors own 89.62% of the company's stock.
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of IQVIA from a "hold" rating to a "buy" rating in a research report on Saturday, September 12th. Royal Bank Of Canada lifted their price objective on IQVIA from $247.00 to $319.00 and gave the stock an "outperform" rating in a report on Tuesday, September 29th. UBS Group started coverage on IQVIA in a research note on Wednesday, September 30th. They set a "buy" rating and a $345.00 price objective for the company. BMO Capital Markets increased their target price on IQVIA from $270.00 to $305.00 in a report on Monday, October 19th. Finally, Mizuho raised their target price on IQVIA from $275.00 to $300.00 and gave the company an "outperform" rating in a research report on Wednesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $294.21.
View Our Latest Analysis on IQV
IQVIA Price Performance
IQVIA stock opened at $250.21 on Friday. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $284.50. The firm has a market capitalization of $41.23 billion, a price-to-earnings ratio of 30.40, a PEG ratio of 2.29 and a beta of 1.16. The company has a fifty day simple moving average of $267.34 and a 200-day simple moving average of $212.35. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 2.18.
IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, beating analysts' consensus estimates of $3.26 by $0.08. The business had revenue of $4.43 billion during the quarter, compared to analysts' expectations of $4.37 billion. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The company's quarterly revenue was up 8.0% compared to the same quarter last year. During the same period in the prior year, the business earned $3.00 earnings per share. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 11.53 EPS for the current fiscal year.
Insider Transactions at IQVIA
In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares in the company, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 4,446 shares of the firm's stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $278.83, for a total transaction of $1,239,678.18. Following the completion of the transaction, the insider directly owned 24,989 shares in the company, valued at $6,967,682.87. This trade represents a 15.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.70% of the stock is currently owned by corporate insiders.
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company's offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.